Pfizer And GSK's ViiV Healthcare's Two-Drug HIV Treatment Matches Gilead's Three-Drug Combo In Major Trial
Pfizer And GSK's ViiV Healthcare's Two-Drug HIV Treatment Matches Gilead's Three-Drug Combo In Major Trial
Tuesday, GSK Plc (NYSE:GSK) / Pfizer Inc (NYSE:PFE)-owned ViiV Healthcare said its two-drug HIV regimen Dovato was as effective as Gilead Science Inc's (NASDAQ:GILD) three-drug combo Biktarvy in a head-to-head trial.
週二，紐交所上市的GSK Plc（NYSE:GSK）/輝瑞公司（Pfizer Inc，NYSE:PFE）旗下的ViiV Healthcare宣佈，在一項頭對頭的試驗中，其兩種藥劑治療艾滋病的配方Dovato與蓋利達科學公司（Gilead Science Inc，NASDAQ:GILD）的三種藥劑聯合治療方案Biktarvy同樣有效。
Japanese pharmaceutical company Shionogi & Company is also a stakeholder in ViiV healthcare.
日本藥品公司Shionogi & Company也是ViiV healthcare的股東。
ViiV Healthcare released 48-week findings from PASO DOBLE (GeSIDA 11720 study), the largest head-to-head, phase IV randomized clinical trial (RCT) investigating the 2-drug regimen Dovato (dolutegravir/lamivudine [DTG/3TC]) compared to the 3-drug regime Biktarvy (bictegravir/ emtricitabine/tenofovir alafenamide fumarate [BIC/FTC/TAF]) for virologically suppressed HIV-1 patients.
ViiV Healthcare發佈了PASO DOBLE（GeSIDA 11720研究）48周的結果，這是目前最大的針對病毒學抑制艾滋病毒患者的2種藥物聯合療法Dovato（多特格韋/拉米夫定[DTG/3TC]）與3種藥物聯合療法Biktarvy（比克特格韋/恩曲他濱韋酯/阿拉芬酸富馬酸鹽[BIC/FTC/TAF]）進行頭對頭，第四階段隨機臨床試驗（RCT）研究。
Findings showed that switching to DTG/3TC demonstrated non-inferior efficacy in maintaining viral suppression compared with switching to BIC/FTC/TAF.
結果顯示，轉換到DTG/3TC組維持病毒抑制的療效與轉換到BIC/FTC/TAF組相當。
In the PASO DOBLE clinical trial, 553 patients switched treatment to either Dovato (n=277) or Biktarvy (n=276).
在PASO DOBLE臨床試驗中，553名患者轉換到Dovato（n=277）或Biktarvy（n=276）。
The study found in a key secondary endpoint that weight increased significantly more in participants who switched to BIC/FTC/TAF than in those who switched to DTG/3TC through week 48.
研究發現，在一個關鍵的次要終點方面，與在DTG/3TC組轉換的參與者相比，轉換到BIC/FTC/TAF組的參與者體重顯著增加，達到了48周。
The proportion of participants with weight gain greater than 5% was significantly higher for Biktarvy, at 29.9%, compared to 20% for Dovato.
體重增加超過5%的患者比例，Biktarvy明顯高於Dovato，分別爲29.9％和20％。
Weight change with Dovato was consistent across genders and prior regimens. However, participants switching from abacavir-based regimens experienced a 45% higher rate of over 5% weight gain with Biktarvy compared to Dovato (30.6% vs. 21.1%). When switching from TDF-based regimens, the weight gain rate with Biktarvy was about twice as high as with Dovato (40.7% vs. 19.5%).
Dovato的體重變化在不同性別和治療方案之間是一致的。但是，從阿巴卡韋基治療方案轉換的參與者與從Dovato轉換相比，與Biktarvy相比，體重增加超過5%的比率高45％（30.6％對21.1％）。轉換自TDF基治療方案的患者，Biktarvy的體重增加率大約是Dovato的兩倍（40.7％對19.5％）。
In 2023, Dovato generated sales of 1.82 billion pounds, while Biktarvy brought in $11.8 billion.
2023年，Dovato的銷售額爲18.2億英鎊，而Biktarvy的銷售額爲118億美元。